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transmission of multidrug-resistant 
tuberculosis, mainly because we 
were modelling a setting with low 
multidrug-resistant tuberculosis. 
However, our approach could be used 
in contexts with a higher prevalence 
of multidrug-resistant tuberculosis 
than Tanzania because both the eﬀ ect 
on the level of multidrug-resistant 
tuberculosis diagnosed and the 
related costs of multidrug-resistant 
tuberculosis treatment were included 
with an assumption that the incidence 
of multidrug-resistant tuberculosis 
is in proportion to the number of 
tuberculosis cases. If this assumption 
is not applicable, further research 
would be needed to model effect 
on multidrug-resistant tuberculosis 
transmission of alternative diagnostic 
algorithms. We agree wholeheartedly 
with Dheda and colleagues’ comment 
that the sensitivities of the model 
should be seen as flags that inform 
programmatic implementation. 
Indeed, we ran many simulations 
testing several of the assumptions, 
which we described in our appendix.
Finally, an important element of our 
study is that, rather than focusing on 
the eﬀ ect of one diagnostic test, our 
modelling deliberately models whole 
diagnostic algorithms and alternative 
placements of new diagnostic tests 
within those algorithms. We think that 
this is an important element of our 
approach that helps to compare whole 
algorithms involving microscopy (eg, 
same-day front-loaded fluorescence 
light-emitting diode microscopy), 
targeted use of Xpert MTB/RIF (eg, 
to HIV-positive or smear-negative 
patients), empirical clinical diagnosis, 
and any combination of the above. 
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Cost-eﬀ ectiveness of 
Xpert MTB/RIF and 
investing in health care 
in Africa
We welcome the Comment by Keertan 
Dheda and colleagues (October 
issue)1 about our modelling study2 
that assessed the effects and cost-
eﬀ ectiveness of several new tuberculosis 
diagnostic algorithms for adult 
pulmonary tuberculosis in Tanzania. 
However, we would argue that some 
key points about the importance of the 
work have been omitted. 
Dheda and colleagues point out that 
the accuracy of clinical diagnoses for 
tuberculosis or empirical tuberculosis 
treatment is highly setting-specific. 
We agree with this viewpoint; indeed, 
we would suggest that tuberculosis 
diagnosis in general is highly setting-
specific, which, rather than being a 
limitation of our study, is precisely 
why our study is relevant. Variations in 
test quality, patient pathways, levels of 
centralisation, and many other factors 
mean that accurate assessment of 
the effect of any new diagnostic 
algorithm needs to take these factors 
into account. These variations are 
why the detailed and comprehensive 
modelling approach of our study is 
needed at the national level to support 
national policy decision makers to 
make decisions in the context of 
their country’s needs. Although each 
context needs modelling that is ﬁ tted 
to local data, the approach used in our 
study can be generalised and adapted 
to model other contexts.
Contrary to the implication in the 
Comment by Dheda and colleagues 
that our modelling assumptions result 
in much lower levels of overtreatment 
than reported in South Africa, our 
modelling approach suggested that, 
on the basis of Tanzania’s national 
data for smear-positive and smear-
negative tuberculosis cases, alongside 
assumptions for the sensitivity and 
speciﬁ city of microscopy and clinical 
diagnosis,3,4 more than 40% of the 
smear-negative tuberculosis cases are 
falsely diagnosed as tuberculosis on 
clinical grounds. This false diagnosis 
leads to high levels of overtreatment 
consistent with that referenced by 
Dheda and colleagues in South Africa, 
Uganda, and Kenya.5,6 Results of our 
study suggest that the use of Xpert 
MTB/RIF as the primary diagnostic 
method would lead to both a reduction 
in underdiagnosis in patients with 
microbiologically deﬁ ned tuberculosis 
as a result of the accuracy of the test, 
and a reduction in overdiagnosis in 
patients without microbiologically 
confirmed tuberculosis as a result 
of a reduction in empirical clinical 
diagnoses. The net result is not much 
change in overall numbers of patients 
placed on tuberculosis treatment. We 
believe that outcomes would be much 
the same in countries with a similar 
prevalence of HIV and smear-negative 
tuberculosis and with decentralised 
tuberculosis programmes. Importantly, 
the patient outcome information 
reported in our study focuses on true 
cures, and takes into account the 
overtreatment of tuberculosis. This 
proportion of true cures is in contrast 
to the proportion of tuberculosis cases 
reported as successfully treated (88% 
in Tanzania), which will usually include 
some cases as successfully treated even 
when tuberculosis treatment was not 
necessary.
We agree with Dheda and colleagues 
that the costs incurred by patients are 
very important and affect whether 
patients complete diagnosis or 
not. To this end, we reported the 
projected eﬀ ect of diﬀ erent diagnostic 
algorithms on the number of visits to 
a diagnostic centre and the diagnostic 
loss to follow-up. Both these 
outcomes have the potential to be 
reduced by implementation of Xpert 
MTB/RIF. We also detail how the eﬀ ect 
of new diagnostics on patients’ costs 
could be projected using our study 
approach and report our ﬁ ndings in 
our appendix using data from Malawi.
Dheda and colleagues point out 
that we did not speciﬁ cally model the 
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